Information Provided By:
Fly News Breaks for January 22, 2020
Jan 22, 2020 | 09:34 EDT
BMO Capital analyst Gary Nachman raised his price target on Horizon Therapeutics to $46 and kept his Outperform rating. The analyst says the FDA approval of the company's Tepezza for thyroid eye disease, or TED, came well ahead of its March 8th PDUFA and featured a "clean label" supporting the broad applicability in TED with a $200K per course price tag coming at the high end of the anticipated range. Nachman further cites Horizon Therapeutics' strong execution with its key marketed product Krystexxa and expects these two programs to be sources of upside going forward.
News For HZNP From the Last 2 Days
There are no results for your query HZNP